opublikowano wyniki 72-tygodniowego badania fazy II z semaglutydem u chorych z NASH potwierdzon biopsyjnie (A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis PubMed)
Sensitivity analyses around key model inputs and assumptions showed that the base case findings were robust
Products are not intended for use in the diagnosis, cure, mitigation, treatment, or prevention of any disease, nor for any clinical, diagnostic, or therapeutic use
It increases both norepinephrine and dopamine levels
Graphical abstract Similar content being viewed by others 1 Introduction Cancer represents an abnormal mass of tissue, the growth of which exceeds and is uncoordinated with that of the surrounding normal tissues and persists in the same excessive manner after cessation of the stimuli which caused the change as described by Willis [1]
(link to article in the comments) #GLP1s #WeightLossDrugs #EmployeeBenefits To view or add a comment, sign in 27% of employers say GLP-1 weight-loss drugs made up more than 15% of their total annual claims in 2024
